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Therapeutical implicationAbstract Psychiatric disorders are often considered as simple imbalances between a limited num-
ber of cerebral neurotransmitters. In fact, it is more complicated than this ‘‘simple approach’’ and
each psychiatric disorder constitutes network dysfunction within which several agents and factors
are implicated. Thus, the therapeutical perspectives and implications are as vast and as numerous
as the diversity of those network dysfunctions. Furthermore, the description of factors inﬂuencing
diseases prognoses and treatment efﬁcacy indicates new elements to consider both in therapies and
drug researches.
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96 A. Ghanemi1. IntroductionWith their divers etiologies and incidences, psychiatric disor-
ders constitute real health problems in both developed and
underdeveloped countries. Among those health problems, anx-
iety disorders are the most common mental illnesses in the
world (Hill and Gorzalka, 2009). It subsumes a variety of neu-
rological disorders i.e., obsessive–compulsive disorders
(OCD), panic disorders (PD), post-traumatic stress disorder
(PTSD), generalized anxiety disorder (GAD) and social anxi-
ety disorder (Machado et al., 2012; Zlomuzica et al., 2012),
whereas depression is considered as a severe psychiatric disor-
der of complex etiology, it is associated with different molecu-
lar and neurochemical changes in the neural networks
(Krishnan and Nestler, 2010). More important, the large and
important family of G protein coupled receptors (GPCRs) is
implicated in some psychiatric disorders. Indeed, in addition
to the alteration of the functions of multiple GPCRs in the
depressive state, antidepressant treatment inﬂuences GPCR
activity (Catapano and Manji, 2007; Dunlop and Nemeroff,
2007) which indicates, due to the pharmacological importance
GPCRs have among the modern pharmacotherapies, promis-
ing therapeutic possibilities.2. Pathophysiology and emerging potentials: network
dysfunctions rather than limited pathway imbalances
Whereas divers neurotransmitters are involved in the patho-
physiology, most researches on mood and affective status have
mainly focused on the roles of brain systems containing mono-
amines (e.g., dopamine, norepinephrine, and serotonin). In-
deed, depression has often been linked with reduced
noradrenaline (NE) (Frazer, 1997; Koch et al., 2002) may be
because agents, with mood elevating effects, enhance extracel-
lular concentrations of monoamines and prolong their actions
(Di Chiara and Imperato, 1988; Koch et al., 2002; Ritz et al.,
1987). In fact, kappa opioid receptors (KORs) play important
roles in both anxiety and depression, thus KOR antagonists
may have effects on both phenomena’s prognoses. Indeed,
KOR antagonists have anxiolytic effects in rodents (Knoll
et al., 2007) and some studies have pointed that KOR antago-
nists might constitute a treatment for anhedonia, which can
promote self-medication with psychostimulants (Bruchas
et al., 2010; Markou et al., 1998). On the other hand, several
papers have indicated that KOR antagonists constitute a po-
tential treatment of addictive disorders (Aldrich et al., 2009;
Beardsley et al., 2005; Jackson et al., 2010; Walker and Koob,
2008; Wee et al., 2009) which include some aspects of nicotine-
associated withdrawal that can be blocked by KOR antago-
nists (Jackson et al., 2010). Moreover, deregulation of brain re-
ward systems and increased sensitivity to stress are two
observed phenomena among addicts during the period of drug
dependence (Kreek and Koob, 1998). Importantly, a chronic
exposure to drugs of abuse or psychostimulants, such as opi-
ates, nicotine and ethanol, has been linked with an increase
in the activity of the KOR system through the enhancement
of the neuropeptide dynorphine expression. Dynorphin consti-
tutes endogenous ligand of KORs (Shippenberg et al., 2007)
that plays a role in the dysphoric component of stress (Land
et al., 2008) and KOR antagonist pathway includes the activa-tion of KORs that produces depression or depressive-like
behaviors in humans and rodents (Bals-Kubik et al., 1989;
Pfeiffer et al., 1986; Todtenkopf et al., 2004; Wadenberg,
2003; Walker and Koob, 2008). Furthermore, KOR blockade
has antidepressant-like effects (Mague et al., 2003; McLaugh-
lin et al., 2003; Newton et al., 2002; Pliakas et al., 2001) thus;
blockade of KORs before exposure to a stressor might attenu-
ate the development of stress-induced behavioral adaptations.
Another publication has given additive data which suggest that
KOR antagonists would be most effective if administrated as a
prophylactic treatment in depressive-like behaviors (Chartoff
et al., 2012) whereas, another article pointed the ability endog-
enous opioid systems have in the activity of monoamine sys-
tems’ cerebral modiﬁcation (Snyder and Pasternak, 2003;
Leone et al., 1991; Johnson and North, 1992), moreover, mes-
ocorticolimbic system, Prefrontal cortex (PFC), amygdala, and
septum which are involved in motivation, emotion, mood and
affective states (Nestler and Carlezon, 2006) have been shown
to express KORs (Mansour et al., 1995) thus, may explain the
effects attributed to KOR ligands on mood regulation
(Carlezon et al., 2009). Importantly, it is admitted that all
addictive drugs promote DA function (Di Chiara and Impera-
to, 1988; Wise and Bozarth, 1987) and buprenorphine, which is
an opioid with an ability to disrupt KOR function, has been
described with antidepressant effects (Bodkin et al., 1995)
which link more KOR function to depression, moreover, this
concept has been further fueled by ﬁndings. Indeed, KOR ago-
nists, like spiradoline and enadoline, were pointed as a possible
medication for mood disorders and, while spiradoline can
reduce tics frequency and provoke sedation in patients with
Tourette’s Syndrome (Chappell et al., 1993), enadoline can
produce sedation, depersonalization, visual distortions, confu-
sion and paranoia (Walsh et al., 2001a,b). On the other hand
salvinorin A was also described with antidepressant effects
(Carlezon et al., 2009). Furthermore, KOR agonists may affect
NE release in some brain regions (Adamson et al., 1989;
Allgaier et al., 1989; Ford et al., 2006). It has also been indi-
cated that KOR agonists may decrease mood (Cohen and
Murphy, 2008) and can, with acute dosing, lower mood as well
(Bucheler et al., 2005; Cohen and Murphy, 2008). Local
administration of KOR agonists into the nucleus accumbens
(NAc) decreases DA concentrations within NAc (Donzanti
et al., 1992; Spanagel et al., 1992). Together, these data high-
light strongly the importance of KOR system as a potential
target for novel drugs and provide key elements which suggest
that KOR-speciﬁc ligands may constitute starting molecules to
develop new drugs for mood disorders including depression,
mania, bipolar disorder and might be for mood stabilization
as well (Carlezon et al., 2009). Because the properties that have
been linked to KOR ligand activities and the inter-inﬂuences
KO have with many neurotransmitters, a particular pharmaco-
vigilance is highlighted herein.
More advances in neurochemistry and neurobiology, will
surely, allow the development of novel, safe and effective ther-
apies including pharmacotherapy, psychotherapy and cogni-
tive-behavioral therapy (Li et al., 2012; Ressler and
Mayberg, 2007). These advances are fueled by recent discover-
ies. Illustratively, the amygdaloid neurons are involved in emo-
tions and fear regulations, thus amygdala is known as a fear
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2000). Whereas glutamatergic and GABAergic systems are
implicated in anxiety, learning and memory processes
(Roozendaal et al., 2009), serotonin (5-HT), due to the impor-
tant functions it play mainly -but not only- within the amyg-
dala, 5-HT has a regulatory role in the anxiety behaviors
and among the ﬁfteen serotonin receptors, 5-HT1A and
5-HT2C receptors are relatively abundant in the amygdala
(Li et al., 2012). Moreover, polymorphisms of the gene coding
for the serotonin transporter have been linked to stress in-
duced depression (Caspi et al., 2003; Vergne and Nemeroff,
2006). In pharmacology, 5-HT1A receptor agonists, such as
buspirone due to its anxiolytic effects, have constituted an
anxiolytic drug (De Vry, 1995; Li et al., 2012). A recent study
on the roles of 5-HT1A and 5-HT2C receptors in the anxiety-
like behaviors within the amygdala (Li et al., 2012) concluded
that: ‘‘5 HT1A receptors produce anxiolytic and 5-HT2C
receptors produce anxiogenic effects’’ so, both receptors play
important roles in anxiety-like behavior regulating phenom-
ena. A previous paper (Holmes, 2008) indicated also that stim-
ulating 5-HT1A receptors and 5-HT2C receptors produces
anxiolytic and anxiogenic effects respectively. These results
constitute advances in neuropharmacology by illustrating
how 5-HT1A receptors in amygdale constitute a potential tar-
get for anxiolytic drugs and a therapeutical research key in
anxiety behavior area whereas, the anxiogenesis property of
5-HT2C receptor stimulation might be used in experimental
models of studies that could allow further understanding and
exploitation of anxiety phenomena, then build animal models
for eventual anxiolytic drug trials.
The above stated illustrations constitute selected examples
to furthers exemplify the potentials of targeting the implicated
neuronal network. The pharmacological properties and the
therapeutical applications of targeting such neuroreceptors
and their associated pathways derive not only form the physi-
ological roles they play but also from the pathogenesis process
they control.3. New therapeutic perspectives: traditional Chinese medicine as
antidepressant?
Following up the previous serotonergic-related line of thought,
interesting therapeutic possibilities from targeting the seroto-
nergic and other monoaminergic pathways are not limited to
the use of receptor agonists or antagonists but include the
inhibition of the reuptake of the extracellular central mono-
amine and not only by chemical compounds. Indeed, a new
natural potential treatment for antidepressant-like activity
has recently been described and researches in pharmacognosy
have pointed out a traditional Chinese herbal medicine; fruc-
tose Akebiae extracts (FAE) (Jin et al., 2012) which is a novel
triple inhibitor of monoamine transporters with a pharmaco-
dynamic mechanism involves the inhibition of the reuptake of
the extracellular central monoamines (serotonin (5-HT), nor-
epinephrine (NE) and dopamine (DA)) via binding to all the
corresponding three-monoamine transporters (NET, SERT
and DAT), respectively thus, enhances the correspondent sig-
naling which results in the potent antidepressant-like activity
of the FAE (Jin et al., 2012). Further complementary studies
are still required to further elucidate the analytical data rela-
tive to the constitutive active ingredients of FAE especiallythat toxicological investigations are to be carried out. These
ﬁndings, in addition of highlighting a part of the complex
network that depression involves, reﬂect the importance of
GPCR-related system as a target for traditional Chinese med-
icine (TDM).
4. New factors inﬂuencing pharmacological efﬁcacy and
therapeutic choices
Based on the patient proﬁle and the pathophysiological status,
novel advances are providing new elements about how to select
the best treatments. For neurological disorders, such as depres-
sion and anxiety the toxicological proﬁle of the patient’s
conditions can be very crucial for therapeutic choices. Indeed,
whereas the co-morbid nicotine addiction phenomenon is of-
ten observed among depressive patients, citalopram, imipra-
mine and reboxetine (antidepressant agents) have been
shown to reduce nicotine-induced hyperactivity in rats which
points the possible implications of both serotonin and norepi-
nephrine in the conditional stimulus (CS) effects of nicotine
(Dion et al., 2012), therefore, the depression treatment choice
for depressive patients with nicotine addiction must selectively
consider the appropriate antidepressant, especially that even-
tual implications of other neurotransmitters in the nicotine
addiction phenomenon make the relevant pharmacovigilance
more important.
On the other hand, studies on the intercorrelation between
brain norepinephrine (NE) arousal system and stress axis dem-
onstrated sex-related differences in mood disorder manifesta-
tion (Valentino et al., 2012). Furthermore, sex, strain and
age differences in response to KOR agonists have also been de-
scribed in rats (Barrett et al., 2002; Smith and French, 2002).
Therefore, targeted population and age are also two factors
that result in distinct pathogenic conditions which result in dif-
ferent reactions against therapies because of the pathophysio-
logical effects on drugs’ efﬁcacy and undesirable side effects.
Indeed, nowadays, depression and anxiety disorder treatments
increasingly use selective serotonin reuptake inhibitors (SSRIs)
(Murray et al., 2004; Zito et al., 2002) and among all the SSRI
only ﬂuoxetine is registered for the treatment of major depres-
sive disorder (MDD) for children over eight years old and this,
in spite of the limited data we have regarding its effects on the
late developing brain during the Prediger et al. (2012) adoles-
cence period (Klomp et al., 2012), whereas we know more
about Long-term (side-) effects of ﬂuoxetine in both adulthood
(Benmansour et al., 1999; Cipriani et al., 2007; Mourilhe and
Stokes, 1998; Racagni and Popoli, 2008; Schule, 2007) and
perinatal periods (Alwan and Friedman, 2009; Borue et al.,
2007; Homberg et al., 2011; Oberlander et al., 2006). Neverthe-
less, in 2004 we have seen a black box warning, from both the
Food and Drug Administration (FDA) and European Medi-
cines Agency (EMA), drawing attention to the side-effects
associated with the SSRI use and that have been shown for
children, adolescents and young adults, the most serious are
higher occurrence of psychiatric and/or behavioral adverse
events such as sleep disturbances and agitation (Bridge et al.,
2007; Hammad et al., 2006; Wilens et al., 2002; Wohlfarth
et al., 2006), moreover, adolescence has a critical importance
for ‘neuronal imprinting’ effects in which long term drug expo-
sure effects are expressed in adult life. To further investigate
the effects of chronic SSRI treatment on the serotoninergic
98 A. Ghanemisystem, a recent study on chronic ﬂuoxetine-treated juvenile
and adult rats has been carried out (Klomp et al., 2012). It
used non-invasive pharmacological MRI (phMRI) and indi-
cated that chronic ﬂuoxetine treatment has age-dependent
effects on brain responses which supports the ‘equal but oppo-
site’ theory of Anderson (Andersen, 2003). The importance of
such studies is the age-population they focus on. Indeed, we
may conclude, via comparison with previous mentioned stud-
ies that in different age-populations and for the same SSRI
treatment different side effects can appear. The same study
describes also the diverse effects that serotonin has on the
brain activities which suggest that future researches may pro-
vide more details about both SSRI side effects and new aspects
of antidepressants’ pharmacodynamics.5. Antidepressants and neurogenesis: new inclusion criteria of
treatments choices?
Searching for depression-related advances led us to new
emerging hypothesis that suggested a link between some anti-
depressant treatment and neurogenesis. In fact, the neurogen-
esis hypothesis of affective disorders postulates that the
generation of neurons in the postnatal hippocampal dentate
gyrus is involved in both etiology and treatment efﬁcacy of
major depressive disorder (MDD)’’ (Petrik et al., 2012). The
hypothesis concept appeared in the 1990s (Brezun and
Daszuta, 1999; Gould et al., 1992) and since, researches on
the hippocampus, stress, monoamines and MDD were carried
out (Conrad, 2008; Hirschfeld, 2000; Lopez-Munoz and
Alamo, 2009; McEwen, 2000; Sapolsky, 2000; Sheline et al.,
2002) which provided further data about the neurogenesis
hypothesis. Results have pointed that chronic, but not acute
antidepressant treatment, increased subgranular zone (SGZ)
proliferation and neurogenesis (Malberg et al., 2000). In addi-
tion, the neurogenesis hypothesis includes posttraumatic
stress disorder (PTSD) and other potential relevances for anx-
iety disorders (Bremner et al., 2008). This neurogenesis
hypothesis could contribute to develop and test eventual
new antidepressant drugs and add new agents to the mood-
related disorder pharmacotherapies (Petrik et al., 2012), for
that matter it may provide complementary elements for the
understanding of both monoamines-related and anxiety disor-
ders. However, the possible exploitation of the existent links
between antidepressant treatment and neurogenesis proper-
ties, for pharmacological purposes, in cell cultures and even
in vivo, remains promising.6. Perspectives
Carlezon et al. have written: ‘‘Much current research is ‘‘drug-
centric’’ (focusing on the mechanisms by which currently avail-
able psychotropic drugs act) rather than ‘‘brain-centric’’
(focusing on the abnormal states that are treated by these
drugs)’’ (Carlezon et al., 2009) which indicates that new ways
of thinking or new ways of explaining the pathogenesis phe-
nomena may help us to go further and think about developing
new drugs rather that ‘‘copy’’ the existent agents. Further-
more, more lights should be put on the new factors that may
inﬂuence the neuroreceptors especially those which belong to
the GPCR family (Ghanemi et al., 2013) and thus, includethe related pharmacodynamical inﬂuence within the future
studies. However, we still require a better understanding of
both brain physiology and pathophysiological concepts espe-
cially that psychiatry needs drugs that are safer, act faster,
and with fewer side effects.
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